LAM (Lymphangioleiomyomatosis): The Rare Lung Disease Almost Exclusive to Women
Lymphangioleiomyomatosis, universally known as LAM, is a rare and progressive lung disease that almost exclusively affects women. Abnormal smooth muscle-like cells grow uncontrollably in the lungs, lymphatic vessels, and kidneys, forming cysts that gradually destroy healthy lung tissue. Over time, this destruction robs the lungs of their ability to function properly, leading to progressive breathlessness and reduced quality of life.
LAM is so rare that many women wait years before receiving a correct diagnosis. Its symptoms mimic asthma, chronic obstructive pulmonary disease, and other common respiratory conditions, leading clinicians down misleading diagnostic pathways. Yet LAM is biologically fascinating, driven by specific genetic mutations, almost entirely oestrogen-linked in its behaviour, and increasingly manageable with targeted therapy. Understanding LAM fully transforms the diagnostic journey for the women and clinicians who encounter it.
What Is LAM?
LAM is a neoplastic condition, meaning it involves abnormal cell proliferation, though it does not behave like typical cancer. Abnormal cells called LAM cells, which resemble smooth muscle cells, invade the lungs, lymphatic channels, and sometimes the kidneys and other abdominal organs. These cells form thin-walled cysts throughout both lungs, progressively replacing functional lung tissue.
The name Lymphangioleiomyomatosis reflects its cellular origins. Lymphangio refers to lymphatic vessel involvement, leiomyo describes smooth muscle-like cell characteristics, and matosis indicates a proliferative process. Together, these elements describe a condition involving abnormal smooth muscle-like cell growth within lymphatic vessels and lung tissue.
Who Develops LAM?
LAM almost exclusively affects women of reproductive age, typically between 20 and 50 years old. The strong association with reproductive age strongly implicates female sex hormones, particularly oestrogen, in driving LAM cell proliferation. Rare cases in men have been reported, almost exclusively in those with a genetic syndrome called tuberous sclerosis complex.
Global prevalence estimates suggest LAM affects approximately three to five women per million population. Due to widespread underdiagnosis and diagnostic delays, true prevalence is likely higher than reported figures suggest.
Types of LAM
Doctors classify LAM into two distinct forms based on whether the disease occurs in association with a genetic syndrome or arises independently.
Sporadic LAM
Sporadic LAM occurs in women without tuberous sclerosis complex and arises from spontaneous somatic mutations, meaning mutations that develop in body cells after birth rather than being inherited. These mutations occur in genes called TSC1 or TSC2, but only in specific cells rather than throughout the body. Sporadic LAM accounts for the majority of LAM cases worldwide.
Women with sporadic LAM typically present in their thirties and forties with progressive breathlessness or an acute episode of pneumothorax. They have no family history of LAM or related genetic conditions.
TSC-Associated LAM
TSC-associated LAM develops in women who have tuberous sclerosis complex, an inherited genetic disorder causing benign tumours to grow in multiple organs including the brain, kidneys, skin, heart, and lungs. LAM occurs in approximately 30 to 40 percent of women with tuberous sclerosis complex.
TSC-associated LAM tends to develop at a younger age than sporadic LAM and may be detected incidentally during routine surveillance imaging for tuberous sclerosis, before significant symptoms develop. Because tuberous sclerosis is a multisystem condition, women with TSC-associated LAM require coordinated multidisciplinary care.
The Biology Behind LAM
Understanding LAM’s biology illuminates why it behaves so distinctively and why targeted therapy has become so important.
TSC Gene Mutations and mTOR Pathway
LAM cells carry mutations in TSC1 or TSC2 genes, which normally produce proteins called hamartin and tuberin. These proteins act as tumour suppressors, braking the activity of a critical cellular growth regulator called mTOR, which stands for mechanistic target of rapamycin.
When TSC1 or TSC2 mutations disable this braking mechanism, the mTOR pathway becomes hyperactive. Cells proliferate uncontrollably, migrate abnormally, and resist normal cell death signals. This fundamental biological understanding directly led to the development of mTOR inhibitor medications that form the cornerstone of modern LAM treatment.
The Oestrogen Connection
The near-exclusive occurrence of LAM in women of reproductive age, its acceleration during pregnancy, and its reported improvement after menopause all point powerfully toward oestrogen as a disease driver. LAM cells express oestrogen and progesterone receptors, suggesting hormones directly stimulate their proliferation.
Pregnancy significantly worsens LAM in some women, with accelerated lung function decline and increased pneumothorax risk observed during gestation. This hormonal sensitivity has historically led clinicians to use hormonal manipulation as a treatment strategy, though evidence for this approach remains limited compared to mTOR inhibitor therapy.
How LAM Destroys Lung Tissue
LAM cells form clusters within the lung and produce enzymes called matrix metalloproteinases that digest and destroy the normal structural framework of lung tissue. This destruction creates the thin-walled cysts characteristic of LAM on imaging. As more lung tissue converts to cysts, the lungs lose their elasticity and gas exchange capacity progressively.
Lymphatic involvement allows LAM cells to spread through lymphatic channels, explaining why the disease affects lymph nodes, the thoracic duct, and abdominal lymphatics in addition to the lungs.
Symptoms of LAM
LAM produces a range of symptoms that reflect progressive lung destruction, pneumothorax, lymphatic involvement, and associated organ manifestations.
Progressive Breathlessness
Progressive exertional breathlessness is the most prominent and ultimately most disabling symptom of LAM. Initially, women notice breathlessness only during strenuous exercise. Over months and years, breathlessness occurs with increasingly mild exertion, eventually limiting daily activities significantly.
This gradual progression explains why many women attribute early breathlessness to fitness, ageing, or asthma, delaying their LAM diagnosis by an average of four to five years in many series.
Pneumothorax
Pneumothorax, meaning collapse of a lung due to air leaking into the chest cavity, is the presenting event in approximately 50 percent of LAM cases. Cysts near the lung surface rupture spontaneously, releasing air into the pleural space and causing sudden, sharp chest pain and acute breathlessness.
Recurrent pneumothorax is a defining feature of LAM. After a first spontaneous pneumothorax in a woman of reproductive age, clinicians should actively consider LAM as a diagnosis and pursue appropriate investigation.
Chylothorax and Chylous Ascites
LAM disrupts lymphatic vessels throughout the chest and abdomen, causing lymphatic fluid called chyle to leak into body cavities. Chylothorax refers to milky, fat-rich lymphatic fluid accumulating in the pleural space around the lung. Chylous ascites describes similar fluid accumulating in the abdominal cavity.
Both complications cause breathlessness, abdominal discomfort, and nutritional depletion because lymphatic fluid contains significant quantities of fat, protein, and immune cells. These complications require specific dietary and procedural management strategies.
Abdominal and Renal Manifestations
Angiomyolipomas are benign kidney tumours containing blood vessels, smooth muscle, and fat that develop in approximately 50 to 60 percent of women with sporadic LAM and even more commonly in those with TSC-associated LAM. These tumours can grow to large sizes and carry a risk of spontaneous haemorrhage, meaning bleeding, which can be life-threatening.
Abdominal lymphangioleiomyomas, cystic masses arising in abdominal lymphatic vessels, cause abdominal pain, bloating, and sometimes urinary symptoms due to compression of adjacent structures.
Fatigue and Reduced Exercise Capacity
Profound fatigue and dramatically reduced exercise capacity affect most women with significant LAM. These symptoms reflect both reduced lung function and the physiological burden of a chronic progressive illness. Many women report that fatigue significantly limits their professional, family, and social lives, sometimes more than breathlessness alone.
Diagnosing LAM
Diagnosing LAM requires clinical suspicion, characteristic imaging findings, biochemical markers, and sometimes tissue biopsy. The diagnostic pathway has become considerably clearer with increasing physician awareness and improved biomarker availability.
High-Resolution CT Scanning
High-resolution CT scanning of the chest is the central diagnostic investigation for LAM. In LAM, CT reveals characteristic diffuse thin-walled lung cysts distributed uniformly throughout both lungs. These cysts appear round, well-defined, and typically range from two to five millimetres in diameter, though larger cysts develop in more advanced disease.
The combination of this characteristic bilateral cystic pattern in a woman of reproductive age is highly suggestive of LAM. CT also assesses cyst burden, providing a measure of disease severity and baseline for monitoring progression.
Serum VEGF-D Measurement
Vascular endothelial growth factor D, abbreviated VEGF-D, is a protein released by LAM cells into the bloodstream. Elevated serum VEGF-D levels, specifically above 800 picograms per millilitre, confirm LAM diagnosis when combined with characteristic CT findings, avoiding the need for lung biopsy in most cases.
This non-invasive diagnostic approach represents a significant advance, sparing women from the risks of surgical lung biopsy while maintaining diagnostic accuracy. VEGF-D measurement is now incorporated into international LAM diagnostic guidelines.
Lung Function Testing
Pulmonary function testing in LAM typically demonstrates an obstructive or mixed obstructive-restrictive pattern with reduced diffusion capacity. Airflow obstruction reflects cyst formation disrupting small airway architecture. Diffusion capacity decline reflects progressive loss of functional lung tissue available for gas exchange.
Serial pulmonary function testing every six to twelve months monitors disease progression and guides treatment decisions, particularly regarding when to initiate mTOR inhibitor therapy.
Lung Biopsy
When CT findings are atypical or VEGF-D levels are not diagnostically elevated, lung biopsy provides definitive histological confirmation. Transbronchial biopsy through a bronchoscope offers the least invasive option, though diagnostic yield is modest. Video-assisted thoracoscopic surgical biopsy yields definitive pathological diagnosis in nearly all cases.
Pathological examination reveals clusters of LAM cells with characteristic spindle and epithelioid morphology, cyst formation, and immunohistochemical staining patterns distinctive of LAM.
Genetic Testing
Genetic testing for TSC1 and TSC2 mutations is recommended in all newly diagnosed LAM patients to distinguish sporadic from TSC-associated disease and to guide family counselling. Women with TSC-associated LAM require comprehensive evaluation for other tuberous sclerosis manifestations including brain, kidney, skin, and cardiac involvement.
Treatment of LAM
LAM management has been transformed by the development of mTOR inhibitor therapy, though treatment remains focused on slowing progression rather than curing the disease.
Sirolimus: The Landmark Treatment
Sirolimus, also called rapamycin, is an mTOR inhibitor that directly targets the hyperactive signalling pathway driving LAM cell proliferation. The landmark MILES trial, published in 2011, demonstrated that sirolimus stabilised lung function decline, improved quality of life, and reduced functional impairment in women with LAM compared to placebo.
Sirolimus represents the first disease-modifying therapy proven effective for LAM. It does not cure the disease or reverse existing cystic damage, but it meaningfully slows the rate of lung function decline in treated women.
Who Should Receive Sirolimus?
Current guidelines recommend sirolimus for women with LAM who demonstrate declining lung function, significant symptoms, or chylous complications. Women with mild disease and stable lung function may be monitored without treatment, with sirolimus initiated when evidence of progression emerges.
Treatment with sirolimus requires careful monitoring for side effects including mouth ulcers, infections, skin rashes, and elevated cholesterol levels. Regular blood level monitoring ensures therapeutic dosing while minimising toxicity.
Everolimus as an Alternative
Everolimus is another mTOR inhibitor with a similar mechanism to sirolimus. It shows particular utility in TSC-associated LAM and for treating renal angiomyolipomas in women with LAM. Everolimus carries a strong evidence base for reducing angiomyolipoma volume and is approved for this indication in tuberous sclerosis complex.
The choice between sirolimus and everolimus depends on individual patient characteristics, associated organ manifestations, and side effect profiles.
Managing Pneumothorax
Recurrent pneumothorax management in LAM requires specific consideration given the very high recurrence rates, approaching 70 percent after a first episode. Pleurodesis, a procedure fusing the lung lining to the chest wall to prevent future pneumothorax, is strongly recommended after a first LAM-related pneumothorax.
Chemical pleurodesis using talc or mechanical pleurodesis through video-assisted thoracoscopic surgery are both effective options. Clinicians balance pneumothorax prevention against the potential impact of pleurodesis on future lung transplantation candidacy.
Bronchodilator Therapy
Many women with LAM demonstrate airflow obstruction that partially reverses with bronchodilator medications. Inhaled bronchodilators, including beta-agonists and anticholinergic agents, improve breathlessness and exercise capacity in LAM patients with reversible airflow obstruction.
Bronchodilators do not modify disease progression but provide meaningful symptomatic relief as an adjunct to disease-modifying mTOR inhibitor therapy.
Hormonal Treatments
Historically, clinicians used hormonal manipulation strategies including progesterone therapy, oophorectomy, and gonadotropin-releasing hormone analogues to suppress oestrogen and slow LAM progression. Evidence for these approaches is limited compared to mTOR inhibitors, and most guidelines now reserve hormonal treatments for specific situations such as pregnancy-related disease acceleration or management of refractory chylous complications.
Oestrogen-containing contraceptives and hormone replacement therapy are generally avoided in women with LAM given the disease’s oestrogen sensitivity.
Pulmonary Rehabilitation
Pulmonary rehabilitation programmes improve exercise capacity, reduce breathlessness, and enhance quality of life in women with LAM. Structured exercise training, breathing techniques, and education components all contribute to functional improvement. Regular participation in pulmonary rehabilitation is recommended as part of comprehensive LAM management alongside disease-modifying therapy.
Lung Transplantation
For women who progress to end-stage LAM despite optimal medical therapy, lung transplantation offers the most significant survival benefit. LAM is an established indication for bilateral lung transplantation. Outcomes after transplantation for LAM compare favourably with other indications, with good medium-term survival reported in experienced centres.
Importantly, LAM can recur in transplanted lungs, though recurrence rates appear low and rarely cause clinically significant problems. Early referral to transplant centres is essential for women with advanced LAM and rapidly declining lung function.
Living With LAM
Managing LAM extends well beyond medical therapy. The physical, emotional, reproductive, and social dimensions of living with a rare progressive lung disease demand comprehensive support.
Pregnancy and Reproductive Decisions
Pregnancy carries significant risks for women with LAM. Oestrogen surges during pregnancy can accelerate lung function decline and dramatically increase pneumothorax risk. Some women experience irreversible worsening of LAM during pregnancy. Comprehensive counselling about these risks before conception is essential.
Women with LAM who wish to become pregnant require close monitoring by both a pulmonologist experienced in LAM and a high-risk obstetrician throughout pregnancy. Decisions about conception must carefully weigh personal reproductive goals against current disease severity.
Air Travel Considerations
Air travel is generally safe for women with LAM who have adequate lung function and no recent pneumothorax. However, reduced cabin pressure at altitude can cause existing cysts to expand, increasing pneumothorax risk. Women with severe cystic disease or recent pneumothorax should discuss air travel safety individually with their LAM specialist before flying.
Psychological Support and Patient Communities
A LAM diagnosis carries profound psychological impact. The rarity of the condition, the uncertainty of its prognosis, and the challenges of explaining it to family, friends, and employers all generate significant emotional burden. Access to psychological support, specialist LAM nurses, and patient organisations including The LAM Foundation provides community, education, and advocacy.
Peer networks of women living with LAM offer uniquely powerful support, connecting women who share experiences that few outside their community can fully understand.
Frequently Asked Questions
What is LAM disease?
Lymphangioleiomyomatosis, or LAM, is a rare progressive lung disease caused by the abnormal growth of smooth muscle-like cells that form cysts throughout the lungs. It almost exclusively affects women of reproductive age. The disease involves mutations in TSC1 or TSC2 genes, leading to hyperactive mTOR signalling that drives uncontrolled cell proliferation and progressive destruction of lung tissue.
Is LAM only found in women?
LAM occurs almost exclusively in women, particularly those of reproductive age. This near-exclusivity reflects the disease’s sensitivity to oestrogen, which drives LAM cell proliferation. Extremely rare cases in men occur almost solely in those with tuberous sclerosis complex. The hormonal dependence of LAM makes it one of medicine’s most strikingly gender-specific diseases.
How is LAM diagnosed?
LAM diagnosis combines characteristic bilateral lung cysts on high-resolution CT scanning with elevated serum VEGF-D levels in women with compatible symptoms. This combination confirms LAM without biopsy in most cases. Lung biopsy provides definitive histological diagnosis when imaging and biomarker findings are inconclusive. Genetic testing identifies TSC1 and TSC2 mutations, distinguishing sporadic from TSC-associated LAM.
Can LAM be cured?
Currently, no cure exists for LAM. However, sirolimus, an mTOR inhibitor, effectively slows lung function decline and represents a genuine disease-modifying treatment. Lung transplantation offers significant survival benefit for women with advanced end-stage disease. Ongoing research into LAM biology continues to identify new therapeutic targets with the potential to transform outcomes further in the coming years.
Does pregnancy worsen LAM?
Yes. Pregnancy carries significant risks for women with LAM. The hormonal surges of pregnancy, particularly oestrogen elevation, can accelerate lung function decline and increase pneumothorax risk substantially. Some women experience permanent worsening of LAM during or after pregnancy. Pre-conception counselling by a LAM specialist is essential for all women with LAM who are considering pregnancy.
What is the life expectancy for someone with LAM?
Life expectancy in LAM has improved significantly with better diagnosis and effective mTOR inhibitor therapy. Studies report median transplant-free survival of ten or more years from symptom onset in many cohorts. Disease course varies considerably, with some women experiencing rapid progression and others remaining relatively stable for many years. Early diagnosis, regular monitoring, and timely initiation of sirolimus optimise long-term outcomes.
Conclusion
LAM is a remarkable and complex disease that sits at the intersection of genetics, hormonal biology, and progressive lung destruction. Its near-exclusive occurrence in women reflects a profound hormonal dependency that makes it biologically unique among lung diseases. For too long, the rarity of LAM consigned affected women to lengthy diagnostic odysseys, often measured in years of misdiagnosis before the correct answer emerged.
The discovery that mTOR pathway hyperactivation drives LAM, and the subsequent development of sirolimus as an effective disease-modifying therapy, represent genuine scientific triumphs for a condition that previously had no proven treatment options. Women with LAM today have access to a therapy that meaningfully slows their disease, along with clear monitoring frameworks, better surgical options for pneumothorax prevention, and a growing transplant evidence base for advanced disease.
The work is far from finished. A cure remains elusive. Diagnostic delays persist globally. Reproductive decisions carry burdens no woman should face without comprehensive, expert guidance. Greater awareness among clinicians who encounter breathless young women, stronger research funding for rare diseases, and continued growth of LAM patient communities all represent the next essential steps toward a future where every woman with LAM receives an early diagnosis, effective treatment, and the full support she deserves.
Disclaimer:
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, or medical guidance related to any health condition.
References:
- Tuberous sclerosis affects virtually every organ system though some remain clinically silent.Â
- Tuberous sclerosis complex is an autosomal dominant genetic disorder characterized by hamartoma development in multiple organ systems from TSC1 or TSC2 gene mutations.Â
- The lungs sit inside the chest cavity and are surrounded by two thin membranes called the pleura.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
